Bcwm LLC Sells 35,322 Shares of Medtronic PLC $MDT

Key Points

• Bcwm LLC reduced its Medtronic holding by 30.0%, selling 35,322 shares in Q3 and now owns 82,357 shares valued at about $7.84 million (roughly 2.3% of its portfolio).
• EVP Harry Skip Kiil executed an insider sale of 52,524 shares at an average price of $97.71 on Feb. 19, cutting his direct ownership by 61.58% to 32,768 shares.
• Medtronic slightly beat quarterly estimates (EPS $1.36 vs. $1.34; revenue $9.02B vs. $8.89B), set FY2026 guidance of 5.62–5.66 EPS, and declared a $0.71 quarterly dividend (3.3% yield; ex-dividend Mar. 27).

Bcwm LLC lessened its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 30.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,357 shares of the medical technology company's stock after selling 35,322 shares during the quarter. Medtronic accounts for approximately 2.3% of Bcwm LLC's investment portfolio, making the stock its 18th biggest holding. Bcwm LLC's holdings in Medtronic were worth $7,844,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MDT. Norges Bank acquired a new position in shares of Medtronic during the 2nd quarter worth about $1,432,698,000. Barclays PLC increased its position in shares of Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock valued at $650,604,000 after acquiring an additional 3,492,192 shares during the last quarter. Schroder Investment Management Group raised its holdings in Medtronic by 78.3% during the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company's stock worth $717,143,000 after acquiring an additional 3,307,211 shares in the last quarter. Guinness Asset Management LTD acquired a new position in Medtronic during the third quarter valued at approximately $275,556,000. Finally, Wellington Management Group LLP grew its stake in Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock valued at $970,456,000 after purchasing an additional 2,658,981 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.26% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MDT shares. Needham & Company LLC reiterated a "buy" rating and set a $120.00 price objective on shares of Medtronic in a research note on Tuesday. Wall Street Zen cut shares of Medtronic from a "buy" rating to a "hold" rating in a research note on Sunday, March 1st. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a "neutral" rating in a report on Wednesday, November 19th. UBS Group reaffirmed a "neutral" rating and set a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Finally, Morgan Stanley increased their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an "overweight" rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.74.

Medtronic Stock Performance

MDT opened at $87.05 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The business has a 50 day moving average of $97.96 and a 200-day moving average of $96.87. The stock has a market cap of $111.77 billion, a price-to-earnings ratio of 24.25, a PEG ratio of 2.23 and a beta of 0.71.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the firm earned $1.38 EPS. The firm's revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.